EPCAM and neoplasm: Comparison of the three groups of patients—divided by the proportion of EpCAMhigh, EpCAMlow, and EpCAM-negative CTCs—by molecular subtype, tumor size, grade, and lymphogenous metastasis did not reveal any differences.